Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. Stocks on the Move-BlackBerry, AcelRx, Repros, Diamond Foods, Nike

Fri, 26th Sep 2014 12:35

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)

U.S. stock index futures were inching higher on Friday aftermajor indexes suffered their biggest drop since July, ahead ofdata on economic growth and consumer optimism.

Dow Jones industrial average futures were up 0.25percent at 16,942, S&P 500 futures were up 0.19 percentat 1,965.25 and Nasdaq 100 futures were up 0.24 percentat 4,017.

** BLACKBERRY LTD, Thursday close $9.8, +1.73 pctpremarket

The Canadian smartphone maker said itssecond-quarter loss narrowed to $207 million from $965 million ayear earlier in early sign turnaround efforts may be working.Still, revenue fell nearly 42 percent to $916 million, missingthe average analyst estimate of $949.63 million.

** ACELRX PHARMACEUTICALS INC, Thursday close$6.72, -17.71 pct premarket

The U.S. FDA said it would take another six months to reviewa marketing application on the drugmaker's recently rejectedpain management device.

** REPROS THERAPEUTICS INC, Thursday close $8.96,+11.61 pct premarket

The drug developer said its experimental drug to treat lowtestosterone, Androxal, met the main goal of late-stage study.

The U.S FDA has granted the company a pre-drug approvalmeeting to discuss Androxal in the first half of November.

** DIAMOND FOODS INC, Thursday close $26.62, +5.18pct premarket

The packaged food company reported better-than-expectedquarterly adjusted profit and sales, helped by higher demand forsnacks such as Pop Secret popcorn and Kettle potato chips.

** MICRON TECHNOLOGY INC, Thursday close $31.7, +6.91pct premarket

The memory chipmaker posted fiscal fourth-quarter resultsand gave a revenue outlook that impressed Wall Street as signsof stabilization in the personal computer industry supporteddemand for DRAM chips.

At least ten brokerages including Stifel Nicolaus andRaymond James raised their price targets on the stock.

** NIKE INC, Thursday close $79.75, +7.57 pctpremarket

The world's largest sportswear maker reported abetter-than-expected quarterly profit as it gains market sharein Europe and focuses on higher-margin products such as Flyknitsoccer boots.

Janney Capital Markets upgraded the stock to "buy" from"neutral" and at least 13 brokerages raised their price target.

** FINISH LINE INC, Thursday close $29.41, -10.06pct premarket

The footwear retailer posted a quarterly profit that missedWall Street's estimate, hurt by lower demand for basketballsporting goods. Its merchandise inventory increases 11.5percent.

** ALIBABA GROUP HOLDING LTD, Thursday close$88.92, +0.90 pct premarket

The newest way to bet on the fortunes of Chinese e-commerceheavyweight Alibaba will debut on Monday when its stock optionsgo live for trading, and investors should look for the initialaction to be very busy, but also choppy and potentially pricey.Options market traders say Alibaba puts and calls will likelysee heavy demand given the interest shown so far in the stocksince its record-setting $25 billion IPO last week.

** INTEL CORP Thursday close $34.14, +0.76 pctpremarket

Intel said it will pay as much as $1.5 billion for a 20percent stake in two mobile chipmakers with ties to the Chinesegovernment, in the hopes of catching up in a smartphone chipindustry dominated by rival Qualcomm Inc.

** APPLE INC, Thursday close $97.87, +0.92 pctpremarket

Apple broke its silence on complaints about bending iPhones,hours after withdrawing a glitch-ridden software update as thecompany struggles to restore momentum to the rollout of itslatest phones.

** ASTRAZENECA, Thursday close $70.99, +1.25 pctpremarket

The British pharmaceutical company said an expandeduse of its IRESSA treatment for lung cancer has been recommendedfor approval by European regulators. (Compiled by Shailaja Sharma in Bangalore; Editing by SavioD'Souza)

More News
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 07:43

LONDON BRIEFING: Stocks seen lower; Aviva buys AIG's UK protection arm

(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.

Read more
22 Sep 2023 08:42

LONDON MARKET OPEN: Stocks slip after central bank rate calls

(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.

Read more
22 Sep 2023 08:13

TOP NEWS: AstraZeneca's datopotamab deruxtecan shows positive results

(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.

Read more
22 Sep 2023 07:27

AstraZeneca reports positive findings from breast cancer threatment trial

(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

Read more
20 Sep 2023 08:44

TOP NEWS: AstraZeneca's rare disease business buys Pfizer portfolio

(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.

Read more
15 Sep 2023 15:27

AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday.

Read more
14 Sep 2023 08:25

Smith & Nephew brings BT Chief Financial Officer Simon Lowth to board

(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.